Premium
Immunogenicity of a combined schedule of 7‐valent pneumococcal conjugate vaccine followed by a 23‐valent polysaccharide vaccine in adult recipients of heart or lung transplants
Author(s) -
Gattringer R.,
Winkler H.,
Roedler S.,
Jaksch P.,
Herkner H.,
Burgmann H.
Publication year - 2011
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2011.00628.x
Subject(s) - medicine , pneumococcal polysaccharide vaccine , immunogenicity , pneumococcal conjugate vaccine , conjugate vaccine , conjugate , immunology , streptococcus pneumoniae , microbiology and biotechnology , antigen , pneumococcal disease , mathematical analysis , mathematics , biology , antibiotics
R. Gattringer, H. Winkler, S. Roedler, P. Jaksch, H. Herkner, H. Burgmann. Immunogenicity of a combined schedule of 7‐valent pneumococcal conjugate vaccine followed by a 23‐valent polysaccharide vaccine in adult recipients of heart or lung transplants.
Transpl Infect Dis 2011: 13: 540–544. All rights reserved Abstract: A combined schedule of 7‐valent pneumococcal conjugate vaccine (PCV7) followed by 23‐valent pneumococcal polysaccharide vaccine (PPV23) was evaluated retrospectively in 26 adult recipients of heart or lung transplants. PCV7 was immunogenic in these patients but there appeared to be no benefit from the additional PPV23 dose.